This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

Digital twin opens way to effective treatment of inflammatory diseases

Digital twin opens way to effective treatment of inflammatory diseases
A vision of how digital twins can be used to tailor drugs: (A) Patients with different immune diseases. (B) Computers construct (C) digital twins of each patient's disease mechanisms. These interact in molecular programs, controlled by (D) switch proteins, which are measured in blood or tissue to (E) find the dominant protein(s) at which to target therapy. Illustration: The research group. Credit: Karolinska Institutet

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently available drugs have little effect on many patients. Using so-called digital twins, researchers at Karolinska Institutet have now obtained a deeper understanding of the "off and on" proteins that control these diseases. The study, which is published in Cell Reports Medicine, can lead to more personalized drug therapies.

Many patients with inflammatory diseases such as , Crohn's disease and ulcerative colitis, never feel fully healthy despite being on medication. It is a problem that causes significant suffering and expense.

In an inflammatory disease, thousands of genes alter the way they interact in different organs and cell types. Moreover, the varies from one patient to another with the same diagnosis, and even within the same patient at different times.

It is exceedingly difficult to diagnose and treat such complex and varied changes. In a project that has been underway for five years, researchers from a constellation of institutions including Karolinska Institutet in Sweden have been trying to solve this problem and tailor drugs to individual patients by constructing and data-processing their , i.e. digital models of each patient's unique disease mechanisms.

Now, the research group has found a possible solution: the changes can be organized in molecular programs. These molecular programs are regulated by a limited number of "off and on" switch proteins, of which some are known targets for drugs such as TNF inhibitors. But it is not a therapeutic option that helps everyone.

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently available drugs have little effect on many patients. Using so-called digital twins, researchers at Karolinska Institutet have now obtained a deeper understanding of the “off and on” proteins that control these diseases. The study, which is published in Cell Reports Medicine, can lead to more personalized drug therapies. Credit: Karolinska Institutet

"Our analyses of patients who responded or didn't respond to TNF therapy revealed different switch proteins in different individuals," says the study's corresponding author Mikael Benson, researcher at the Department of Clinical Science, Intervention and Technology, Karolinska Institutet. "Another important discovery was that the proteins did not switch off the diseases but were more like dimmer switches that raised or lowered the disease programs."

Every physiological process can be described with mathematical equations. This advanced digital modeling technique can be adjusted to a patient's unique circumstances by analyzing the activity of each and every gene in thousands of individual cells from blood and tissue. Such a digital twin can be used to calculate the physiological outcome if a condition changes, such as the dosage of a drugs.

Digital twins have revealed to the researchers new opportunities for the effective treatment of serious diseases.

"The methods can be developed to tailor the right combination of drugs for 'on' proteins for individual patients," Dr. Benson continues. "The programs we describe will be made available to the research community so that more can be done of patients with different immune diseases."

In the current study, the researchers combined analyses of a mouse model of rheumatoid arthritis and digital twins of human patients with various .

"Even though only the joints were inflamed in mice, we found that thousands of genes changed their activity in different in ten organs, including the skin, spleen, liver and lungs," says Dr. Benson. "As far as I'm aware, this is the first time science has obtained such a broad picture of how many organs are affected in rheumatoid arthritis. This is partly due to the difficulty of physically sampling so many different organs."

More information: Mikael Benson, Multi-organ single cell analysis reveals an on/off switch system with potential for personalized treatment of immunological diseases, Cell Reports Medicine (2023). DOI: 10.1016/j.xcrm.2023.100956. www.cell.com/cell-reports-medi … 2666-3791(23)00048-4

Journal information: Cell Reports Medicine
Citation: Digital twin opens way to effective treatment of inflammatory diseases (2023, February 28) retrieved 26 February 2024 from https://medicalxpress.com/news/2023-02-digital-twin-effective-treatment-inflammatory.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

'Digital twins'—An aid to tailor medication to individual patients

115 shares

Feedback to editors